- Home
- Equipment
- micronesia
- tumor targeting
Show results for
Refine by
Tumor Targeting Equipment & Supplies In Micronesia
70 equipment items found
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
The proprietary ROCK platform enables a tumor-targeted approach that can be tailored across hematological and solid tumors. The ROCK (Redirected Optimized Cell Killing) platform allows for a modular approach to generating customizable ICE (innate cell engager) molecules. High-affinity ICE (innate cell engager) molecules, which are created using ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
CYNK-CAR candidates are being developed as allogeneic, off-the-shelf approaches through gene modification of human placental hematopoietic stem cell-derived natural killer (NK) cells. Various CAR constructs against hematological and solid tumor targets are under pre-clinical ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
4-1BB mAb-based, tumor antigen targeting bispecific ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
MHI-148 is a near-infrared heptamethine cyanine dye with tumor-targeting properties for cancer detection, diagnosis and research. MHI-148 is immediately taken up and accumulated by lysosomes and mitochondria of tumor cells, but not in lysosomes and mitochondria of normal ...
Manufactured by:Immatics N.V. based inTuebingen, GERMANY
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel biologics allows any T cell in the body to become activated and attack the tumor, regardless of the T ...
Manufactured by:Atlanthera based inSaint-Herblain Cedex, FRANCE
Specific targeting of tumor bone tissue, Potent antitumor activity, Low systemic toxicity, Prevention of bone ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells ...
Manufactured by:Isotopia Molecular Imaging based inPetah Tikva, ISRAEL
Lutetium-177 (Lu-177) is being widely used as a promising radionuclide for targeted therapy and is emerging as a game-changing theranostic isotope for the treatment of neuroendocrine tumors, metastatic castration-resistant prostate cancer (mCRPC) along with its development for new carrier molecules that can provide selective targeting for ...
Manufactured by:Xstrahl based inNorcross, GEORGIA (US) (USA)
This system leverages the advanced FLASH-RT technique, which administers ultra-high dose rates of radiation, significantly surpassing conventional methods. This approach aims to effectively target tumors while minimizing damage to surrounding healthy tissues, making it pivotal for translational cancer research. The system's adaptability for spatially fractionated ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of ...
by:Pars Isotope Co based inTehran, IRAN
The PARS-LUTOTATE theranostic radiopharmaceutical kit is an innovative solution formulated as a single vial for the effective treatment of neuroendocrine tumors. It utilizes the Lu-177 radioisotope, enabling the radiopharmaceutical to selectively target neuroendocrine tumor cells, facilitating their complete destruction. This procedure not only ...
Manufactured by:Nanjing ChiRial Biomaterial Co., Ltd based inNanjing, CHINA
CRA0066 (R)-5-Methylpyrrolidin-2-one CAS: 21395-93-7. ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory ...
Manufactured by:eTheRNA based inNiel, BELGIUM
Therapeutic area: immuno-oncology; Intra-tumoral (IT) ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for novel small molecule PRMT5 ...
Manufactured by:Precision X-Ray based inMadison, CONNECTICUT (USA)
Mimicking clinical radiotherapy imaging and treatments, our SmART+IB provides CBCT imaging and x-ray irradiation. An adaptable window for beamline integration from your proton source allows for side-by-side comparison between conventional and FLASH treatment ...
by:Pars Isotope Co based inTehran, IRAN
This kit is notable for being the first of its kind globally, and is used in conjunction with the Lu-177 radioisotope. It targets prostate-specific membrane antigen (PSMA), a membrane glycoprotein, the expression of which increases with tumor activity, allowing precise targeting of cancer cells. The binding of this radiopharmaceutical to PSMA ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
XR5944 is an anti-tumor compound with DNA-targeting activity. As a topoisomerase inhibitor, XR5944 can effectively inhibit the activities of topoisomerase I and II. XR5944 shows excellent anti-tumor activity against human and mouse tumor cells in vitro and in vivo. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
XR5944 is an anti-tumor compound with DNA-targeting activity. As a topoisomerase inhibitor, XR5944 can effectively inhibit the activities of topoisomerase I and II. XR5944 shows excellent anti-tumor activity against human and mouse tumor cells in vitro and in vivo. ...